PT-141 (Bremelanotide).
A cyclic peptide that acts on melanocortin receptors in the brain, studied for sexual desire. It works centrally rather than on blood vessels, and the studied route is injection under the skin.
Reviewed March 2026
- Category
- Peptide
What PT-141 (Bremelanotide) is, and what it does.
- Does it work
- It suits adults working with a clinician on low desire, since it is a prescription injectable rather than a supplement ingredient. Anyone considering it needs medical supervision.
- How much to take
- Our record puts the band at 0.5mg to 1.8mg a day, with 2.5mg used as a research condition. Being a prescription injectable, the amount is a clinician's call rather than a shelf choice.
- Time to feel it
- Studied as an on-demand dose taken roughly 45 minutes ahead. Reported effects arrive within a few hours of a dose rather than building across weeks.
- The first dose
- Studied as an on-demand dose taken about 45 minutes ahead. Nausea and flushing are the most frequently recorded effects and often arrive first, alongside a brief rise in blood pressure.
- With regular use
- Its half-life is a few hours, so it doesn't accumulate with repeated use. Repeated melanocortin exposure has been linked with darkened skin and pigmented spots.
- How well tolerated
- Nausea and flushing are common, blood pressure rises briefly while heart rate falls, and repeated melanocortin exposure has been linked with darkened skin. Medical supervision is required.
- How it feels
- People describe flushing, warmth and increased desire in the hours after a dose. Nausea is the most frequently recorded effect and often arrives before anything else.
- The overlooked benefit
- It acts on melanocortin signalling in the brain, not on blood vessels, so its pathway is entirely separate from the nitric oxide route most other options work through.
0.5 to 1.8mg a day is where PT-141 (Bremelanotide) works.
Source: Kingsberg et al., 2019, Obstet Gynecol; FDA approval data
The proof, claim by claim.
These words describe the research, not the molecule's worth. Research strength is how much work stands behind one claim, and it is never a product score.
PT-141 (Bremelanotide) has emerging evidence. Based on 7+ studies.
- sexual desire and arousal in womenRandomised trial
- central melanocortin receptor agonismNarrative review
- erectile response in menRandomised trial
- transient rise in blood pressure with a fall in heart rate after a doseRandomised trial
- nausea and flushing as dose-related effectsRandomised trial
Questions people ask about PT-141 (Bremelanotide).
- When should I take it?
- Timing matters less than consistency. Pick a time that works for you and take it daily.
- Can I take it with other supplements?
- Usually fine. The main thing to watch is not doubling up on the same ingredient from different products. If you're on prescription meds, check with your pharmacist first.
- Any side effects to watch for?
- Most people tolerate it well at recommended doses. GI upset is the most common complaint with any supplement. Start with a lower dose and work up. If something feels off, stop and reassess.
- Who benefits most from this?
- Honestly, most people would benefit more from the basics. But if you've got a specific reason to try it, the risk is generally low.
Why these belong in the same formula. Each row says what the basis is, from settled biochemistry through to a trial that measured the pair.
Bremelanotide raises blood pressure transiently through central melanocortin signalling, and yohimbine raises noradrenaline output by blocking alpha-2 receptors. The two push normal blood pressure the same way and the effect adds.
Caffeine raises catecholamine tone and normal blood pressure modestly through adenosine receptor blockade. Layered onto the transient pressor rise from a melanocortin agonist, the two effects overlap in the same window.
Bremelanotide is a melanocortin receptor agonist that works through central pathways, while arginine is the substrate nitric oxide synthase uses to make nitric oxide in the periphery. The two act at different points, so a formulator pairing them is stacking a central signal with a vascular substrate rather than doubling one mechanism. Arginine tends to lower peripheral vascular resistance, and bremelanotide pharmacology includes a short-lived rise in blood pressure with a fall in heart rate, so the net direction of the pair on blood pressure is not predictable from either alone. No study has measured the combination.
Citrulline escapes first-pass metabolism and is converted to arginine in the kidney, so it raises plasma arginine more reliably than oral arginine does. That gives more substrate for nitric oxide synthesis, a vascular effect that sits downstream of nothing bremelanotide does. Because citrulline tends to nudge blood pressure downward and bremelanotide is documented to nudge it upward for a short period after dosing, the pair is treated as modulating rather than simply additive. The interaction is inferred from each compound's pharmacology, not measured together.
Dietary nitrate is reduced by oral bacteria to nitrite and then to nitric oxide, which tends to lower blood pressure. Bremelanotide's recorded pharmacology runs the other way for a few hours after a dose, with a transient blood pressure increase. Someone combining them is layering two opposing haemodynamic signals, which is worth flagging rather than presenting as reinforcement. Nothing has been measured for the pair.
Tyrosine is the amino acid precursor for dopamine, and central melanocortin signalling of the kind bremelanotide produces engages dopaminergic circuits in the hypothalamus. On paper the two touch the same brain systems from different directions, one at the receptor and one at the precursor pool. This is a mechanistic overlap only; no human work has combined them, and tyrosine loading raises dopamine synthesis mainly when precursor supply is limiting.
Tongkat ali is studied for its effects on the hypothalamic pituitary gonadal axis and on circulating androgen markers, which are hormonal measures rather than outcomes. Bremelanotide does not act on that axis; it agonises melanocortin receptors in the central nervous system. A stack therefore addresses two separate layers of the same physiology, and no trial has tested the two together.
Nothing specific on file for PT-141 (Bremelanotide). Match the label to the daily amount above, and tell your doctor what you take.
Not medical advice. Show the label to your pharmacist.What PT-141 (Bremelanotide) actually does.
It is a small lab-made peptide shaped like a natural hormone, and it switches on melanocortin receptors in the brain.
It signals through the brain rather than by relaxing blood vessels directly.
Digestive enzymes break peptides apart, so swallowing this one would destroy most of it.
The same receptor family controls skin pigment, so repeated use of drugs in this class has been reported to darken skin or freckles.
Getting PT-141 (Bremelanotide) from food.
The whole-food sources on file. A supplement closes the gap, it does not replace dinner.
A gram-for-gram figure (how much of each you would eat to match a dose) will appear here once it is sourced and reviewed. This page will not print a number it cannot cite.
The forms it comes in.
The essence, in one line each.
- Review of compounds acting on penile erection groups melanocortin receptor agonists such as bremelanotide with the centrally acting agents, working through brain pathways rather than on penile blood vessels as PDE5 inhibitors do.Review. Albersen et al., 2010 (Expert opinion on emerging drugs). PMID 20415601 ↗
These are the studies our verdict leans on, chosen from the 6 we read for PT-141 (Bremelanotide). The full linked list is below.
FDA Disclaimer: These statements have not been evaluated by the Food and Drug Administration. This information is for educational purposes only and is not intended to diagnose, treat, cure, or prevent any disease. Consult your healthcare provider before starting any supplement regimen.